Navigation Links
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
Date:5/18/2008

-- Additional Data Demonstrated Higher Overall Maintenance of Healed

Erosive Esophagitis and Symptom Relief versus Placebo --

SAN DIEGO, May 18 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

"The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option," said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing ra
'/>"/>

SOURCE TAP Pharmaceutical Products Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...swire/ -- Access MediQuip, LLC, the nation,s first...dical device management solutions to the healthcar...its corporate headquarters to Lake Mary, Florida. ...growth, includes a major expansion of the Primera ...uary 2010 and relocation and expansion of the Hous...
(Date:11/9/2009)...tCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: IST...ompany,s Bepreve(TM) (bepotastine besilate ophthal...e results were presented in poster sessions at the...lergy, Asthma & Immunology (ACAAI) in Miami Be...Treatment of Ocular Itching with Bepotastine Besil...
(Date:11/9/2009)...wswire/ -- Thomson Reuters today announced the n...eading clinical surveillance solution that enables...me and respond immediately to improve clinical qua...s upgrade is available to current CareFocus custom...ontains several powerful enhancements that improve...
Breaking Medicine Technology:Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 2ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) 3Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Proteins in gel 8982 1PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C F M Group 12767 1PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C F M Group 12767 2PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 1PHT Names VP to Lead Sales of A Claim Payment Solution for Doctors Hospitals 49924 2
...stent may hold clinical edge over Taxus stent at t..., March 31 Early results of the SPIRIT II study,s...Taxus stent in six-month,findings on angiography a...ow, a new analysis shows that after two years, the... may continue to hold a clinical edge over,its pac...
...any,s TAXUS(R) and PROMUS(TM) Stents demonstrate p...mes, NATICK, Mass. and CHICAGO, March 31 Boston,...d positive two-year results,from Abbott,s prospect...ty,SPIRIT II Trial comparing the safety and effica...ting Coronary Stent and Boston Scientific,s,worldw...
Other Medicine Technology:SPIRIT II Explores Long-Term Performance of XIENCE V Stent 2SPIRIT II Explores Long-Term Performance of XIENCE V Stent 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 2Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 3Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms 4
(Date:11/9/2009)... , Fast food chains are o...obesity. A recent poll by Fitness.com.au however f...shoulder the responsibility. , ...ast food chains, and video games were behind Austr...nd Dad are more than just innocent bystanders. A r...
(Date:11/9/2009)... , New study highlights p...health , Rosemont, IL (Vo...ncrease and bone health decreases. Recent research...lcium supplements to help prevent these issues. Ho...ber issue of Sports Health: A Multidisciplinary A...
(Date:11/9/2009)... , LEBANON, Tenn., Nov. 9 Hea...oday announced it will host their inaugural Hospit...3-15, 2010 at the Marriott Renaissance Hotel in Na...pecting more than 100 hospital operating room dire...als and health systems in the country. Some of the...
(Date:11/9/2009)... , DETROIT, Nov. 9 ...armanos Cancer Center has been selected the most p...higan, according to a survey by the National Resea...m.com/cgi-bin/prnh/20071106/KARMANOSLOGO ) ,, ...uestionnaire between September 2008 and August 200...
(Date:11/9/2009)... Study didn,t answer question of why this is so, ...News) -- After a lumpectomy, women with very dense...n the affected breast, a new study shows. , Bre...sed risk of developing breast cancer, and experts ... associated with an increased risk of cancer recur...
Breaking Medicine News(10 mins):Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference 2Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3
...thorities have broken off talks with striking doct...inister's office for about 20 days to demand highe..."There will be no more discussions with the unions...ent had offered pay increases in 2008 but the stri...
...dy has shown that taking selenium supplements may,... The study, published in the Annals of Interna... that selenium supplements cause type 2 diabetes, ...nium is a naturally occurring trace mineral presen...
...tle life fraught with danger, for pre-mature babie...-preemies , as they weigh less than 1000 grams, th... tiny babies. Doctors who care for these low...le. Though advances in medical technology have i...
...irst time, researchers have shown that plant growt...nal light . Using time-lapse photography, ...eagues from the University of California, Davis, a...ming of that growth spurt is controlled by both th...
...ver cases in affluent Singapore have surged to the...levels, official figures showed Tuesday . ...ected last week, the second week in a row that the...nistry and the National Environment Agency said in...
...r to be published in the July issue of Cancer Biol...eports finding a significant link between genetic ...8 and the risk of colorectal cancer. A 10-yea...n in the search for the genes that make a person m...
Other Medicine News:Health News:Selenium Supplements may Increase Type 2 Diabetes Risk 2Health News:Medical Science Strides-No Guarantee For Pre-Mature Babies 2Health News:Advancement in Gene Associated With Colon Cancer 2Health News:Advancement in Gene Associated With Colon Cancer 3Health News:Advancement in Gene Associated With Colon Cancer 4
... make us a leader in this field. With standard ass...laboratory, our Infectious Disease ELISA products ...stency. Our Infectious Disease ELISA menu includes...ological assays including ToRCH, EBV, H. pylori an...
C. Diff-CHEK-30
TOX A/B QUIK CHEK
...e single-well ANA screen and ENA screen ELISAs, as...d 6 individual ENA kits: Sm, Sm/RNP, SS-A (Ro), SS...une ELISA family includes a full line of products ...hyroid Microsomal, MPO, PR3, Rheumatoid Factor and...
Medicine Products: